Dosimetric Parameters of the Heart and Its Substructures in Predicting Cardiac Events or Survival in Patients With Lung Cancer After Radiation Therapy: A Systematic Review and Meta-analysis.

Int J Radiat Oncol Biol PhysJun 13, 2026 (epub)
Clinical ResearchCardiologyOncology (Medical)Radiology (Diagnostic)

Xinyi Li, Yajing Wu, Yao Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the relationship between radiation dose to the whole heart and cardiac substructures and the incidence of cardiac events and survival in 21,645 lung cancer patients. Key findings indicate that left anterior descending (LAD) V15 is significantly associated with major adverse cardiac events (MACE), while mean heart dose (MHD) correlates with survival outcomes.

Key findings

  • LAD V15 was significantly associated with MACE.
  • MHD was significantly associated with survival outcomes.
  • Multiple cardiac substructure parameters were linked to various arrhythmia subtypes.
  • MHD, heart V5/V35/V55, and pericardial doses were significantly associated with pericardial effusion.

Why it matters

Understanding the dosimetric parameters that predict cardiac events and survival can help clinicians optimize radiation therapy plans for lung cancer patients, potentially reducing the risk of radiation-induced heart injury.

Source

PubMed · PMID 42288290

Published in Int J Radiat Oncol Biol Phys. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.